Companies/US/AMRX

AMNEAL PHARMACEUTICALS, INC.

Income flow

Annual
AMRX 10-K Income StatementPeriod 2025-12-31Source 10-K
Affordable Medicines Segment$2BAv KARESegment$745MSpecialty Segment$529MRevenue$3B+8% Y/YGross profit$1B+9% Y/YCost of revenue$2BOperating profit$394M+58% Y/YOperating expenses$719MNet profit$72MTax$11MSG&A$527MR&D & other$192M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$3.0B
  • Affordable Medicines Segment$1.7B57.8%
  • Av KARESegment$745M24.7%
  • Specialty Segment$529M17.5%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).348.3MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).197.3M

Valuation

Trailing PE 57.3 (2025-12-31)PE trend

Fiscal PE1

PeriodEPSClosePE
2025-12-310.2212.657.3

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.